Abstracts by keywords: The Federal Joint Committee
The effects of certain factors evaluated in the benefit assessment process on price negotiations have been examined in other studies (Theidel & Graf von derschulenburg, 2016). The biggest influencing factor in price negotiations is the additional benefit. In this respect, G-BA decisions are stricter than the decisions of other countries regarding the same drugs and indications (Fischer, Heisser, & Stargardt, 2016). A measurement system was proposed to predict G-BA decisions regarding the additional benefit of medicines (Schwandera, Banz, Kaier, & Walzer, 2014). Since clinical data serve as the basis for deciding on the added value of drugs in benefit dossiers, this study focuses on the second important factor that can influence price negotiations: the number of patients in the target populations with a therapeutically significant additional benefit. Particularly in cases where there are multiple patient subgroups and the negotiations are based on a mixed price model, the influence of the submitted patient populations per target group is more pronounced.